Portal de Periódicos da CAPES

Two‐year safety and effectiveness of the platinum chromium everolimus‐eluting stent for the treatment of small vessels and longer lesions

2014; Wiley; Volume: 85; Issue: 2 Linguagem: Inglês

10.1002/ccd.25565

1522-726X

Paul S. Teirstein, Ian T. Meredith, Robert L. Feldman, Abram C. Rabinowitz, Louis Cannon, Tommy C. Lee, Joseph Dens, Christophe Dubois, M. Mooney, Vincent J. Pompili, Shigeru Saito, Dominic J. Allocco, Keith D. Dawkins, Gregg W. Stone,

Antiplatelet Therapy and Cardiovascular Diseases

To report 1- and 2-year clinical outcomes of patients receiving platinum chromium everolimus-eluting stents (PtCr-EES) in the prospective, single-arm PLATINUM small vessel (SV) and long lesion (LL) studies.Small vessel diameter and long lesion length are independently associated with increased risk of adverse cardiac events after drug-eluting stent implantation.The PLATINUM SV study enrolled 94 patients with coronary artery lesions in vessels ≥2.25 mm to 24 to ≤34 mm long in vessels ≥2.50 to ≤4.25 mm in diameter. The primary endpoint for both studies was target lesion failure (TLF) at 1 year compared to a prespecified performance goal based on outcomes with the TAXUS Express paclitaxel-eluting stent in small vessels and long lesions.One-year TLF rates with the PtCr-EES were significantly (P < 0.001) lower than the predetermined performance goals: 2.4% versus 21.1% in the SV cohort and 3.2% versus 19.4% in the LL cohort. Cumulative rates of TLF to 2 years were 4.7% in the SV cohort and 8.8% in the LL cohort. No myocardial infarction or ARC definite/probable stent thromboses occurred in either cohort through 2-year follow-up.The clinical efficacy and safety outcomes observed in these small vessel and long lesion cohorts support the use of the PtCr-EES in the treatment of small diameter vessels and long lesions.